Forma Therapeutics Launches Proposed Public Offering
09 December 2020 - 8:15AM
Business Wire
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a
clinical-stage biopharmaceutical company focused on rare
hematologic diseases and cancers, today announced that it has
launched a proposed public offering of 4,600,000 shares of its
common stock.
All of the shares of common stock in the offering will be
offered by Forma. In addition, Forma expects to grant the
underwriters a 30-day option to purchase up to 690,000 additional
shares of common stock. Together with its existing cash and cash
equivalents, Forma intends to use the net proceeds of the offering
for (i) the development of its lead program FT-4202 in sickle cell
disease including completion of its ongoing Phase 1 clinical trial
and, subject to the results of its Phase 1 clinical trial, the
initiation and conduct of its planned, global pivotal Phase 2/3
clinical trial through Phase 3 dose selection and hemoglobin
futility and hemoglobin improvement, the initiation and conduct of
a clinical trial in pediatric sickle cell disease and the
initiation and conduct of a clinical trial in beta thalassemia
through an initial data readout; (ii) the advancement of FT-7051 in
metastatic castration-resistant prostate cancer, through its
planned Phase 1 clinical trial; and (iii) research and development,
working capital, and general corporate purposes, including funding
pre-approval activities for FT-2102 in acute myeloid leukemia and
the completion of other noncore programs. The proposed offering is
subject to market and other conditions, and there can be no
assurance as to whether or when the proposed offering may be
completed, or as to the actual size or terms of the proposed
offering.
Jefferies, SVB Leerink and Credit Suisse are acting as joint
book-running managers for the offering.
A registration statement relating to these securities has been
filed with the U.S. Securities and Exchange Commission (the “SEC”)
but has not yet become effective. These securities may not be sold,
nor may offers to buy be accepted, prior to the time the
registration statement becomes effective. This press release shall
not constitute an offer to sell or a solicitation of an offer to
buy, nor shall there be any offer or sale of these securities in
any state or other jurisdiction in which such offer, solicitation
or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other
jurisdiction.
The proposed offering will be made only by means of a
prospectus. When available, copies of the preliminary prospectus
may be obtained from: Jefferies LLC, Attention: Equity Syndicate
Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY
10022, by telephone at (877) 821-7388, or by email at
prospectus_department@Jefferies.com; SVB Leerink LLC, Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA
02110, by telephone at (800) 808-7525, ext. 6132, or by email at
syndicate@svbleerink.com; or Credit Suisse Securities (USA) LLC,
Attention: Prospectus Department, 6933 Louis Stephens Drive,
Morrisville, NC 27560, by telephone at (800) 221-1037, or by email
at usa.prospectus@credit-suisse.com.
About Forma Therapeutics
Forma Therapeutics is a clinical-stage biopharmaceutical company
focused on the development and commercialization of novel
therapeutics to transform the lives of patients with rare
hematologic diseases and cancers.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements are any statements that express the
current beliefs and expectations of management, including but not
limited to express or implied statements related to Forma’s ability
to complete the financing and its use of proceeds. The words “may,”
“will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,”
“intend,” “believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “target” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
Any forward-looking statements in this press release are based
on management’s current expectations and beliefs and are subject to
a number of risks, uncertainties and important factors that may
cause actual events or results to differ materially from those
expressed or implied by any forward-looking statements contained in
this press release, including, without limitation, those risks and
uncertainties related to the advancement of Forma’s clinical
programs and other risks identified in Forma’s SEC filings,
including those risks discussed under the heading “Risk Factors” in
its Quarterly Report on Form 10-Q, filed on November 12, 2020, as
well as the risks identified in the registration statement relating
to the offering. Forma cautions you not to place undue reliance on
any forward-looking statements, which speak only as of the date
they are made. Forma disclaims any obligation to publicly update or
revise any such statements to reflect any change in expectations or
in events, conditions or circumstances on which any such statements
may be based, or that may affect the likelihood that actual results
will differ from those set forth in the forward-looking statements.
Moreover, except as required by law, neither Forma nor any other
person assumes responsibility for the accuracy and completeness of
the forward-looking statements included in this press release. Any
forward-looking statements contained in this press release
represent Forma’s views only as of the date hereof and should not
be relied upon as representing its views as of any subsequent
date.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201208006111/en/
Media Contact: Kari Watson, +1 781-235-3060 MacDougall
kwatson@macbiocom.com
Investor Contact: Mario Corso Forma Therapeutics
mcorso@formatherapeutics.com
Forma Therapeutics (NASDAQ:FMTX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Forma Therapeutics (NASDAQ:FMTX)
Historical Stock Chart
From Aug 2023 to Aug 2024